Genetic testing and economic evaluations: a systematic review of the literature.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Epidemiologia & Prevenzione

• Publication date

  2015-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  PMID 26499415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility

  2013cited by this paper
• The economic value of personalized medicine tests: what we know and what we need to know

  2013cited by this paper
• Cost Effectiveness of Pharmacogenomics

  2012cited by this paper
• Developing National Guidance on Genetic Testing for Breast Cancer Predisposition: The Role of Economic Evidence?

  2012cited by this paper
• Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

  2012cited by this paper
• Economic Evaluations Conducted for Assessment of Genetic Testing Technologies: A Systematic Review

  2012cited by this paper
• A review of economic evaluations of genetic testing services and interventions (2004–2009)

  2011cited by this paper
• Expanding the criteria for BRCA mutation testing in breast cancer survivors.

  2010cited by this paper
• Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

  2010cited by this paper
• Evidence-based classification of recommendations on use of genomic tests in clinical practice: Dealing with insufficient evidence

  2010cited by this paper
• Systematic review of pharmacoeconomic studies of pharmacogenomic tests.

  2010cited by this paper
• A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

  2010cited by this paper
• Cost-effectiveness of testing for breast cancer susceptibility genes.

  2009cited by this paper
• Challenges of translating genetic tests into clinical and public health practice

  2009cited by this paper
• Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue

  2009cited by this paper
• Does preventive care save money? Health economics and the presidential candidates.

  2008cited by this paper
• The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

  2007cited by this paper
• Meta-analysis of BRCA1 and BRCA2 penetrance.

  2007cited by this paper
• Genetic screening by DNA technology: A systematic review of health economic evidence

  2006cited by this paper
• Economic analyses of human genetics services: A systematic review

  2005cited by this paper
• Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost‐effectiveness ratio

  2004cited by this paper
• A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.

  2004cited by this paper
• Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies

  2003cited by this paper
• The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant?

  2003cited by this paper
• Costs and Benefits of Diagnosing Familial Breast Cancer

  2002cited by this paper
• Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services.

  2000cited by this paper
• Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.

  1999cited by this paper

• Exploration of familial genetic test result communication among Black women within an academic safety net hospital

  2026cites this paper
• Prevention and early intervention screening for inherited ocular diseases in Saudi Arabia: a national perspective

  2026cites this paper
• Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan

  2025cites this paper
• The health technology assessment approach of the economic value of diagnostic tests: a literature review

  2025influential citation
• Economic evaluations of predictive genetic testing: A scoping review

  2023cites this paper
• Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity

  2023cites this paper
• Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.

  2022cites this paper
• The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis.

  2022cites this paper
• Economic evaluation of genomic/genetic tests: a review and future directions

  2022cites this paper
• Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis

  2022cites this paper
• Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions

  2021cites this paper
• Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine

  2021cites this paper
• Personalised Health Care: Fostering Precision Medicine Advancements for Gaining Population Health Impact

  2021cites this paper
• Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study

  2021cites this paper
• A Systematic Review of the Methodological Quality of Economic Evaluations in Genetic Screening and Testing for Monogenic Disorders

  2021cites this paper
• Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing.

  2020cites this paper
• Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.

  2020cites this paper
• Promises and perils of using genetic tests to predict risk of disease

  2020cites this paper
• Genomics knowledge and attitudes among European public health professionals: Results of a cross-sectional survey

  2020cites this paper
• Evaluation of Predictive Genomic Applications

  2020cites this paper
• Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.

  2019cites this paper
• 1 Cost-effectiveness of precision medicine : a scoping review 2

  2019influential citation
• Cost-effectiveness of precision medicine: a scoping review

  2019cites this paper
• A bronchial‐airway gene‐expression classifier to improve the diagnosis of lung cancer: Clinical outcomes and cost‐effectiveness analysis

  2019cites this paper
• Attitudes toward the right to autonomous decision‐making in psychiatric genetic testing: Controversial and context‐dependent

  2019cites this paper
• Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain

  2019cites this paper
• Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia

  2018cites this paper
• Correction: Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia

  2018cites this paper
• Patient communication of cancer genetic test results in a diverse population.

  2018cites this paper
• Rare disease prevention and treatment: the need for a level playing field.

  2018cites this paper
• Precision Medicine: From Science To Value.

  2018cites this paper
• Overview of Policy, Ethical, and Social Considerations in Genomic and Personalized Medicine

  2017cites this paper
• Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

  2017cites this paper
• Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations

  2016cites this paper
• PERSONALIZED MEDICINE FOR BREAST CANCER: A REVIEW

  year unknowncites this paper